- Home
- LPL vs VKTX Comparison
LPL vs VKTX Comparison
Compare LPL & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPL
- VKTX
- Stock Information
- Founded
- LPL 1985
- VKTX 2012
- Country
- LPL South Korea
- VKTX United States
- Employees
- LPL N/A
- VKTX N/A
- Industry
- LPL Industrial Machinery/Components
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LPL Technology
- VKTX Health Care
- Exchange
- LPL Nasdaq
- VKTX Nasdaq
- Market Cap
- LPL 2.9B
- VKTX 2.8B
- IPO Year
- LPL 2004
- VKTX 2015
- Fundamental
- Price
- LPL $3.43
- VKTX $26.01
- Analyst Decision
- LPL Sell
- VKTX Buy
- Analyst Count
- LPL 2
- VKTX 12
- Target Price
- LPL N/A
- VKTX $84.00
- AVG Volume (30 Days)
- LPL 188.9K
- VKTX 2.9M
- Earning Date
- LPL 07-24-2025
- VKTX 07-23-2025
- Dividend Yield
- LPL N/A
- VKTX N/A
- EPS Growth
- LPL N/A
- VKTX N/A
- EPS
- LPL N/A
- VKTX N/A
- Revenue
- LPL $18,624,457,609.00
- VKTX N/A
- Revenue This Year
- LPL N/A
- VKTX N/A
- Revenue Next Year
- LPL N/A
- VKTX N/A
- P/E Ratio
- LPL N/A
- VKTX N/A
- Revenue Growth
- LPL 23.70
- VKTX N/A
- 52 Week Low
- LPL $2.43
- VKTX $18.92
- 52 Week High
- LPL $4.86
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- LPL 65.55
- VKTX 44.01
- Support Level
- LPL $3.30
- VKTX $25.61
- Resistance Level
- LPL $3.49
- VKTX $30.17
- Average True Range (ATR)
- LPL 0.08
- VKTX 1.43
- MACD
- LPL 0.01
- VKTX -0.21
- Stochastic Oscillator
- LPL 84.52
- VKTX 9.76
About LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.